Evidence map›Paper›PMID 24176642›Full record

ArticleDevelopmental cell2013

Cleavage of TFIIA by Taspase1 activates TRF2-specified mammalian male germ cell programs.

Toshinao Oyama, Satoru Sasagawa, Shugaku Takeda, Rex A Hess, Paul M Lieberman, Emily H Cheng, James J Hsieh

Open access · bronzeAbstract read
In one paragraph

Article in Developmental cell, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. The Core Promoter Is a Regulatory Hub for Developmental Gene Expression.Frontiers in cell and developmental biology · 2021
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. A Strategy To Isolate Modifiers ofG3 (Bethesda, Md.) · 2018
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Toshinao OyamaHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Satoru SasagawaDepartment of Biology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka 537-8511, Japan.
Shugaku TakedaHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Rex A HessVeterinary Biosciences, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, IL 61802, USA.
Paul M LiebermanThe Wistar Institute, Pennsylvania, PA 19104, USA.
Emily H ChengHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA; Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA; Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA.
James J HsiehHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA; Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA; Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA. Electronic address: hsiehj@mskcc.org.
Cornell University · USMemorial Sloan Kettering Cancer Center · USOsaka Medical Center for Cancer and Cardiovascular Diseases · JPThe Wistar Institute · USUniversity of Illinois Urbana-Champaign · US

Funding

Integrated Analyses of Taspase 1 (MLL Cleaving Protease)R01CA119008 · NCI · WASHINGTON UNIVERSITY · PI HSIEH, JAMES J · 2006 to 2010
$1.3M
Molecular Mechanisms of Impaired DAN Damage Response in Leukemia PathogenesisR01CA138505 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI HSIEH, JAMES J · 2013 to 2015
$1.0M
Molecular Mechanisms of Impaired DAN Damage Response in Leukemia PathogenesisU01CA138505 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI HSIEH, JAMES J · 2011 to 2012
$746k
NCI NIH HHS R01 CA119008NCI NIH HHS R01 CA138505NCI NIH HHS R01CA19008NCI NIH HHS U01 CA138505NCI NIH HHS U01CA138505
6 · The paper itself

Abstract

The evolution of tissue-specific general transcription factors (GTFs), such as testis-specific TBP-related factor 2 (TRF2), enables the spatiotemporal expression of highly specialized genetic programs. Taspase1 is a protease that cleaves nuclear factors MLL1, MLL2, TFIIAα-β, and ALFα-β (TFIIAτ). Here, we demonstrate that Taspase1-mediated processing of TFIIAα-β drives mammalian spermatogenesis. Both Taspase1(-/-) and noncleavable TFIIAα-βnc/nc testes release immature germ cells with impaired transcription of Transition proteins (Tnp) and Protamines (Prm), exhibiting chromatin compaction defects and recapitulating those observed with TRF2(-/-) testes. Although the unprocessed TFIIA still complexes with TRF2, this complex is impaired in targeting and thus activating Tnp1 and Prm1 promoters. The current study presents a paradigm in which a protease (Taspase1) cleaves a ubiquitously expressed GTF (TFIIA) to enable tissue-specific (testis) transcription, meeting the demand for sophisticated regulation of distinct subsets of genes in higher organisms.

Indexed as

AnimalsChromosomal Proteins, Non-HistoneEndopeptidasesEnzyme ActivationGene Expression Regulation, DevelopmentalHistone-Lysine N-MethyltransferaseMaleMiceMice, Inbred C57BLMice, KnockoutMyeloid-Lymphoid Leukemia ProteinPromoter Regions, GeneticProtaminesSpermatogenesisSpermatozoaTelomeric Repeat Binding Protein 2Chromosomal Proteins, Non-HistoneEndopeptidasesHistone-Lysine N-MethyltransferaseKmt2a protein, mouseKmt2d protein, mouseMyeloid-Lymphoid Leukemia ProteinPrm1 protein, mouseProtaminesspermatid transition proteinstaspase1, mouseTelomeric Repeat Binding Protein 2Transcription Factor TFIIATRF2 protein, mouse

Identifiers

PMID24176642
PMCPMC3947863
OpenAlexW1992101604

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.